Savara, Inc.
SVRA
Positions held
Your positionsSVRA isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Savara operates in the biotechnology sector, which is known for its potential to innovate and address unmet medical needs, attracting significant investor interest.
- Savara's current ratio stands at 10.132, indicating strong liquidity and the ability to cover short-term liabilities.
- The company's market cap is approximately $955 million, suggesting a substantial presence in the market.
- Savara has not generated any revenue in recent quarters, which raises concerns about its sustainability and growth prospects.
- In the last quarter, Savara reported a net income loss of -40.228 million, continuing a trend of negative earnings with losses increasing over the past year.
- The company's score indicates a 'Strong Sell' signal with a score of -16.00, reflecting negative market sentiment and technical indicators.
Fundamentals
| Market cap | $992.37M | Enterprise value | $1.08B | Trailing P/E | — | Forward P/E | -13.16 |
| PEG | — | Price / book | 8.55 | Beta | 0.20 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -105.5% | ROA | -50.1% | Debt / equity | 0.21 |
| Current ratio | 10.13 | Free cash flow | -$57.19M | Analyst recommendation | strong_buy | Mean target | $11.06 |
| 52w high | $7.01 | 52w low | $3.35 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$40.2M | -$37.3M | -$32.2M | -$29.6M | -$30.4M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$41.0M | -$38.1M | -$33.4M | -$30.3M | -$31.4M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$119M | -$95.9M | -$54.7M | -$38.1M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$123M | -$102M | -$59.2M | -$38.0M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · JPMorgan Initiates Savara at Overweight With $12 Price Target
2026-10-06 · Top Premarket Gainers
2026-08-20 · Savara Announces New Employment Inducement Grant
2026-08-11 · Savara Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-07 · What Insmed Stock's Premium Is Actually Buying
2026-07-22 · Here's Why You Should Add Savara Stock to Your Portfolio Now
Price (daily)
Full chart · RSI · MACD · patterns